EN DE
Watch Labocanna S.A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Labocanna S.A (LCN) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Labocanna S.A stock PLN 0.18, price PLN 0.24, that is 23.7% below the price, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials PL · ISIN PLCCTLS00017

LS Thin data Nov 4, 2026

Labocanna S.A

LCN · WAR
Expensive, weak quality

Our calculation puts a fair price 24% below what the stock costs today.

Quality 40/100
Expensive Growth (revenue 3y +814.5 %/yr in PLN)
Fair value 0.1800 PLN · Overvalued (−23.7%)
Loss-making · -142.0% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 12/100 · thin data
Thin data
⚠ Thinly traded

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.00 PLN 0.1855 PLN Fair Value 0.1800 PLN Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 0.1855 PLN – 3.00 PLN · fair‑value band 0.1300 PLN – 0.2700 PLN · the 0.2360 PLN price screens above the 0.1800 PLN fair value. As of Nov 4, 2026.

Follow Labocanna in your weekly email

Every Wednesday you see whether Labocanna is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Labocanna S.A. engages in the cultivation, production, and distribution of hemp product. The company also offers food and medical hemp-derived products, as well as CBD oil under the Labocanna brand name. It is also involved in commercial real estate management activities.

Show moreShow less

Its products are used in cosmetics, plastics, and textiles. The company was formerly known as Foxbuy.com S.A. and changed its name to Labocanna S.A. in January 2021. Labocanna S.A. was incorporated in 2011 and is headquartered in Koszalin, Poland.

Stock analysis

Labocanna S.A (LCN) currently trades at 0.2360 PLN, while our model-based Fair Value estimate is 0.1800 PLN, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: 0.1300 PLN (bear) to 0.2700 PLN (bull), the price of 0.2360 PLN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Labocanna S.A reported revenue of 2.2M PLN in FY2025 versus 2.9K PLN in FY2022, a compound +814.5%/yr. Reported net income was −873K PLN in FY2025.

Key figures

Market cap 5.0M PLN (≈ $1.3M) Micro · P/S ratio 1.82 · EPS (TTM) −0.1600 PLN · Net margin −142% · Return on equity −78.7% · Return on assets (EBIT) −2.4% · Operating margin −15.9% · Revenue (TTM) 2.6M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 27% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −15% fair-value upside, at −24%, LCN screens richer than that median.

Fair Value models

Bear 0.1300 PLN Fair Value 0.1800 PLN Bull 0.2700 PLN
Price 0.2360 PLN · Downside -23.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 0.1300 PLN 0.1800 PLN 0.2700 PLN 51
All 1 models by family
Asset-Based
NCAV (Graham) 0.1300 PLN 0.1800 PLN 0.2700 PLN 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 42
Debt, balance sheet and risk of trouble
Investment 70
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+121.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+814.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,392.2% (2022) → −7.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LCN screens overvalued: fair value 24% below the price. Compare with Cintas Corporation →

Compare Labocanna S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 230 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −23.7% · Below median
Profitability
Return on assets −6.5% · Bottom 25%
Net margin (12 months) −142.0% · Bottom 25%
Operating margin (12 months) −15.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 5.8% · Below median

Valuation Multiplesvs Specialty Business Services median · lower = cheaper

P/B 0.88× · Cheapest 25%
P/S (12 months) 1.93× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 40
FUTURE (revenue growth)29 · sector 34
PAST (return on equity)0 · sector 39
HEALTH (low debt)0 · sector 94
DIVIDEND (yield)0 · sector 57

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
RB Global, Inc RBA C$132.91 C$143.95 +8% vs LCN
Copart, Inc CPRT $32.62 $35.12 +8% vs LCN
Wolters Kluwer N.V WKL €91.16 €98.05 +8% vs LCN
Global Payments Inc GPN $96.09 $88.05 −8% vs LCN
Brambles Limited BXB A$21.98 A$18.75 −15% vs LCN
Cintas Corporation CTAS $229.03 $188.90 −18% vs LCN
Rentokil Initial plc RTO $24.17 $19.63 −19% vs LCN
Thomson Reuters Corporation TRI $117.23 $70.79 −40% vs LCN
Aramark ARMK $52.33 $23.04 −56% vs LCN
UL Solutions Inc ULS $79.73 $33.46 −58% vs LCN

Explore undervalued stocks

More undervalued Industrials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Labocanna S.A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Labocanna S.A Fair Value". https://www.fairvalue-calculator.com/stock/LCN

Frequently asked questions

Is Labocanna S.A (LCN) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.1800 PLN versus a price of 0.2360 PLN, about 24% lower (overvalued).
What is the fair value of LCN?
Our model-based fair value for Labocanna S.A is 0.1800 PLN (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.2360 PLN.
What is the quality score of LCN?
Labocanna S.A has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Labocanna S.A (LCN)?
Our model-based price target is the fair value of 0.1800 PLN (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 0.1300 PLN, optimistic scenario 0.2700 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Labocanna S.A stock forecast for 2026?
Our models put fair value at 0.1800 PLN, about 24% lower versus a price of 0.2360 PLN (overvalued). Cautious scenario 0.1300 PLN, optimistic scenario 0.2700 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Labocanna S.A (LCN)?
Labocanna S.A reported trailing-twelve-month revenue of about 2.6M PLN (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Labocanna S.A (LCN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Labocanna S.A it is 0.1800 PLN per share (as of Nov 4, 2026), against a price of 0.2360 PLN. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Labocanna S.A stock overvalued or undervalued in 2026?
As of Nov 4, 2026, LCN trades above its calculated fair value: price 0.2360 PLN, fair value 0.1800 PLN, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LCN?
No. The price is what the market pays today (0.2360 PLN); the fair value is what the company's own numbers justify (0.1800 PLN). For Labocanna S.A the two are 0.0560 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Labocanna S.A worth?
The market values Labocanna S.A at about 5.0M PLN (market capitalisation, as of Nov 4, 2026). Per share that is 0.2360 PLN; our models calculate a fair value of 0.1800 PLN per share.
What do the bullish and bearish scenarios say about LCN?
Our models span a range for Labocanna S.A: cautious scenario 0.1300 PLN, base 0.1800 PLN, optimistic 0.2700 PLN per share (as of Nov 4, 2026, price 0.2360 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Labocanna S.A (LCN)?
Balance-sheet figures for Labocanna S.A (as of Nov 4, 2026): return on equity −78.7%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is LCN from its 52-week high?
Labocanna S.A trades at 0.2360 PLN, about 6% below its 52-week high of 0.2500 PLN and 27% above the low of 0.1855 PLN (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1800 PLN is for.
Which stocks are comparable to Labocanna S.A?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Labocanna S.A stock attractive at the current price?
The data as of Nov 4, 2026: price 0.2360 PLN, calculated fair value 0.1800 PLN (−24%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LCN calculated?
We run Labocanna S.A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.1800 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. Labocanna S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Labocanna S.A (LCN)?
The closing price on Nov 4, 2026 was 0.2360 PLN. Our model-based fair value is 0.1800 PLN, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Labocanna S.A right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (0.1300 PLN to 0.2700 PLN) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Labocanna S.A

How large is the market capitalisation of Labocanna S.A (LCN)?
The market capitalisation of Labocanna S.A is 5.0M PLN (≈ $1.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Labocanna S.A (LCN)?
The price-to-sales ratio of Labocanna S.A is 1.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Labocanna S.A (LCN)?
Earnings per share at Labocanna S.A are −0.1600 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Labocanna S.A (LCN)?
The net margin of Labocanna S.A is −142% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Labocanna S.A (LCN)?
The return on equity (ROE) of Labocanna S.A is −78.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Labocanna S.A (LCN)?
On an EBIT basis the return on assets of Labocanna S.A is −2.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Labocanna S.A (LCN)?
The operating margin of Labocanna S.A is −15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Labocanna S.A (LCN)?
Revenue at Labocanna S.A is growing +5.8% versus a year earlier (3y avg +815%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Labocanna S.A (LCN) generate?
The free cash flow of Labocanna S.A is −1.1M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Labocanna S.A in the live analysis

One click puts Labocanna S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.